Aelis Farma Company Description

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.

The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments.

Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.

Aelis Farma SA

Country	France
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Pier Piazza

Contact Details

Address: 1 rue Lafaurie de Monbadon Bordeaux, 33 000 France
Phone	33 5 54 54 23 27
Website	aelisfarma.com

Stock Details

Ticker Symbol	AELIS
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0014007ZB4
SIC Code	2836

Key Executives

Name	Position
Dr. Pier Vincenzo Piazza M.D., Ph.D.	Chief Executive Officer and Director
Marie Line Lefevre	Head of Finance
Stephanie Monlezun	Chief Operating Officer
Lea Floquet	Head of Legal
Arsene Guekam	Chief Corporate Development Officer
Sandy Fabre	Head of Discovery and IP Leader
Aurelie Boucard	Head of Preclinical Development
Helle Mengel	Head of Clinical Development
Corinne Chaimbault	Head of Pharmaceutical Development